Scotiabank Upgrades Legend Biotech to Sector Outperform, Maintains Price Target to $65
Portfolio Pulse from Benzinga Newsdesk
Scotiabank analyst George Farmer upgrades Legend Biotech (NASDAQ:LEGN) from Sector Perform to Sector Outperform, maintaining the price target at $65.

April 17, 2024 | 12:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Legend Biotech upgraded by Scotiabank to Sector Outperform with a maintained price target of $65.
Upgrades by reputable financial institutions like Scotiabank often lead to positive short-term price movements. The reaffirmation of the $65 price target suggests confidence in the company's fundamentals and growth prospects, potentially influencing investor sentiment positively.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100